William Stohl, MD, PhD

Professor of Medicine

Chief, Division of Rheumatology

Is this your profile? Click to edit

Overview

Dr. Stohl’s research focus is on systemic lupus erythematosus (pathogenesis, natural course of disease, treatment, animal models, immunologic disturbances, novel therapeutics); rheumatoid arthritis (pathogenesis, natural course of disease, treatment, animal models, immunologic disturbances, novel therapeutics); Sjogren’s syndrome (biomarkers, novel therapeutics); and B cells (basic biology, role in autoimmune diseases, development of targeted therapies).

Dr. Stohl received his M.D. (1977) and his Ph.D. (1979) from the University Pennsylvania.

Awards

University of Pennsylvania School of Medicine: Upjohn Award, 1979
Arthritis Foundation Southern California Chapter: James R. Klinenberg, M.D. Award, 2003

Research Funding

The vital role of BAFF in the development of SLE
NIH · R01AR050193 · May 16, 2006 – Aug 31, 2012 · Role: Principal Investigator
T CELL CYTOLYTIC ACTIVITY IN SLE
NIH · R01AR041006 · Aug 12, 1993 – Jun 30, 2002 · Role: Principal Investigator
POLYMORPHISM WITHIN T4/LEU3 AND SLE
NIH · R23AR036527 · Jan 1, 1986 – Jun 30, 1989 · Role: Principal Investigator

Media

Publications

The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol. 2012 Jan 09; 30(1):69-77.. View in PubMed
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec; 63(12):3918-30.. View in PubMed
Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012 Mar; 71(3):351-7.. View in PubMed
BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis. PLoS One. 2011; 6(8):e23629.. View in PubMed
Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther. 2011 Jul 06; 13(4):228.. View in PubMed
Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside. Curr Opin Rheumatol. 2011 May; 23(3):305-10.. View in PubMed
B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice. J Immunol. 2011 Apr 15; 186(8):4984-93.. View in PubMed
Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol. 2011 Apr 01; 186(7):4223-33.. View in PubMed
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011 Jan; 70(1):39-46.. View in PubMed
Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity. Arthritis Rheum. 2010 Aug; 62(8):2432-42.. View in PubMed